Chimerix (NASDAQ:CMRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Chimerix (NASDAQ:CMRX) in a research report sent to investors on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on CMRX. HC Wainwright reaffirmed a “neutral” rating and issued a $8.55 target price (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group reaffirmed a “hold” rating and set a $8.50 target price (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush reissued a “neutral” rating and issued a $8.55 price target (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

Chimerix stock opened at $8.52 on Monday. The company has a market capitalization of $799.21 million, a price-to-earnings ratio of -9.06 and a beta of -0.18. The company’s 50 day simple moving average is $6.13 and its 200-day simple moving average is $3.27. Chimerix has a 1 year low of $0.75 and a 1 year high of $8.53.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million. Equities analysts expect that Chimerix will post -0.99 earnings per share for the current year.

Insider Transactions at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CMRX. Deerfield Management Company L.P. Series C acquired a new position in Chimerix in the fourth quarter valued at approximately $13,124,000. Rosalind Advisors Inc. purchased a new position in shares of Chimerix in the 4th quarter valued at $10,614,000. Millennium Management LLC raised its stake in Chimerix by 6.8% during the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock worth $8,900,000 after acquiring an additional 161,795 shares in the last quarter. Marshall Wace LLP lifted its position in Chimerix by 1,318.5% in the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock valued at $7,705,000 after acquiring an additional 2,057,864 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in shares of Chimerix in the 4th quarter valued at about $7,169,000. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.